Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: dalroi who wrote (2483)	1/6/2001 10:57:22 AM
From: scaram(o)uche	Respond to of 52153

Londo, Stefaan...... Thanks! Ugh. Not many of my type to pick from. Guess I'll continue picking at junes and beyond. Given the new ETA receptor antagonist from TXB, the ICOS business plan again has a tad of leverage. Price:book of 30 plus the new $190 million (or so) isn't in my range, however. Book is now about $5, so it's still p:b of about nine. Too rich for what I want. Actually...... will be busy all next week, so this may be largely huff 'n puff.